Literature DB >> 29020795

Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody response.

Marta Starcevic Manning1,2, Mark A Kroenke3, Stephanie A Lee1, Simon E Harrison1, Sarah A Hoofring1, Daniel T Mytych3, Vibha Jawa3,4.   

Abstract

BACKGROUND: Titer methods are commonly used to characterize the magnitude of an antidrug antibody response. Assay S/N is an appealing alternative, but the circumstances under which use of signal-to-noise (S/N) is appropriate have not been well defined.
RESULTS: We validated both titer and S/N-based methods for several therapeutics. S/N correlated strongly with titer both in aggregate and when examined on a per subject basis. Analysis of impact of antibody magnitude on pharmacokinetics yielded the same result using either method. Each assay demonstrated excellent precision, good linearity, and adequate drug tolerance.
CONCLUSION: Under these circumstances, assay S/N is a valid alternative to titer for assessment of the magnitude of an antidrug antibody response.

Keywords:  S/N; antidrug antibody; immunogenicity; titer

Mesh:

Substances:

Year:  2017        PMID: 29020795     DOI: 10.4155/bio-2017-0185

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  3 in total

1.  Anti-drug Antibody Assay Validation: Improved Reporting of the Assay Selectivity via Simpler Positive Control Recovery Data Analysis.

Authors:  Boris Gorovits; Marcela Araya Roldan; Daniel Baltrukonis; Chun-Hua Cai; Jean Donley; Darshana Jani; John Kamerud; Frederick McCush; Jeffrey S Thomas; Ying Wang
Journal:  AAPS J       Date:  2019-06-18       Impact factor: 4.009

Review 2.  Clinical Immunogenicity Risk Assessment for a Fusion Protein.

Authors:  Gizette Sperinde; Diana Montgomery; Daniel T Mytych
Journal:  AAPS J       Date:  2020-04-03       Impact factor: 4.009

3.  Early Adalimumab and Anti-Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients.

Authors:  Xiaoliang Ding; Ruifang Zhu; Jian Wu; Ling Xue; Meihua Gu; Liyan Miao
Journal:  Clin Transl Sci       Date:  2020-02-13       Impact factor: 4.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.